Evaluate the clinical application value of the novel radiolabeled TSPO-targeted molecular probe Gallium \[68Ga\]-DOTA-HK-011 in inflammation imaging of glioma.
Voluntary subjects, patients, or their legal representatives must sign the informed consent form.
There are no restrictions on the gender of volunteers; age must be between 18 and 75 years, inclusive.
Other imaging examination methods (e.g., CT, MRI) show the presence of intracranial lesions.
Patients with brain glioma who are scheduled for surgery or biopsy that will provide final pathological results.
Individuals with a history of allergy to drugs with similar chemical or biological components to TSPO, a history of atopy, or currently suffering from allergic diseases.
Individuals currently participating in other drug clinical studies, or who have previously participated in any drug (excluding vitamins and minerals) clinical studies.
Individuals with other difficult-to-control clinical conditions, such as HIV infection, hepatitis C virus infection, active hepatitis B, other severe chronic infections, or serious mental, neurological, cardiovascular, respiratory, or other systemic diseases.
Red blood cell count (RBC) < 4×10^12/L, white blood cell count (WBC) < 3×10^9/L, hemoglobin < 110 g/L, platelet count (PLT) < 75×10^9/L.